CORT_OUT_1 [2025-03-31 09:06:21 -0400] 1888 Bytes | 558 tokens | Cum: 558 tkns (6.98% of 8k)
==========================================================================

Listen up, partner—it's 9:06:19 AM on Mon Mar 31, 2025 -0400, and I’m revved up about Corcept Therapeutics (CORT), climbing from 54.63 to 105.86. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Corcept Therapeutics:

C1 - Today 08:00AM - Primary Endpoint Met in Corcepts Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
C2 - Mar-28-25 11:30AM - Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report?
C3 - Mar-28-25 11:30AM 09:45AM - Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
C4 - Mar-27-25 12:03PM - ClearBridge Small Cap Fund Q4 2024 Commentary
C5 - Mar-27-25 12:03PM 09:39AM - PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
C6 - Mar-27-25 12:03PM 08:46AM - SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
C7 - Mar-26-25 05:41PM - 3 Reasons to Sell CORT and 1 Stock to Buy Instead
C8 - Mar-21-25 09:40AM - Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Corcept Therapeutics (CORT)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CORT_OUT_3 [2025-03-31 09:06:23 -0400] 564 Bytes | 170 tokens | Cum: 730 tkns (9.12% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1): C1:
**Primary Endpoint Met in Corcepts Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer**
Date: Today 08:00AM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20250331748780/en/

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20250331748780/en/

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CORT_OUT_5 [2025-03-31 09:06:25 -0400] 981 Bytes | 291 tokens | Cum: 1086 tkns (13.58% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T12:05:38Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Aprea Therapeutics (NASDAQ:APRE), Apol...
A2 - 2025-03-31T12:06:00Z - Corcept Therapeutics Incorporated: Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial o...
A3 - 2025-03-31T07:53:58Z - KLP Kapitalforvaltning AS Makes New Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT)...
A4 - 2025-03-30T09:40:00Z - $CORT | ($CORT) Investment Analysis and Advice (CORT)...
A5 - 2025-03-30T08:24:36Z - Segall Bryant & Hamill LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CORT_OUT_7 [2025-03-31 09:06:30 -0400] 1098 Bytes | 336 tokens | Cum: 1424 tkns (17.80% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Monday's Pre-Market Session - Aprea Therapeutics (NASDAQ:APRE), Apollomics (NASDAQ:APLM)**Date: 2025-03-31Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44559530/12-health-care-stocks-moving-in-mondays-pre-market-sessionGainers Citius Oncology CTOR stock moved upwards by 66.9% to $1.11 during Monday's pre-market session. The market value of their outstanding shares is at $79.4 million. Corcept Therapeutics CORT shares rose 44.99% to $79.21. The market value of their outstanding shares is at $8.3 billion. Spruce Biosciences SPRB shares moved upwards by 18.6% to $0.35. The market value of their outstanding shares is at $14.4 million. Apollomics APLM shares rose 17.73% to $8.96. The market value of their outstanding shares is at $9.8 million. Know Labs KNW shares moved upwards

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CORT_OUT_9 [2025-03-31 09:06:31 -0400] 932 Bytes | 295 tokens | Cum: 1871 tkns (23.39% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-11T18:00:00Z - Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight
B2 - 2024-09-19T19:36:39Z - Corcept Moves 6.5% Higher: Will This Strength Last?
B3 - 2024-09-03T20:29:03Z - Corcept Shares Rise More Than 45% in Six Months: Here's Why
B4 - 2024-08-06T10:20:08Z - Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
B5 - 2024-06-26T15:13:00Z - Corcept (CORT) Shares Rise 20% in Three Months: Here's Why
B6 - 2024-06-24T20:15:00Z - Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CORT_OUT_11 [2025-03-31 09:06:35 -0400] 773 Bytes | 212 tokens | Cum: 2085 tkns (26.06% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/11/2995656/0/en/Alcohol-Use-Disorder-Market-Set-for-Remarkable-Growth-During-the-Study-Period-2020-2034-DelveInsight.htmlThe alcohol use disorder market is expected to show positive growth, with growing awareness about AUD and reduced stigma surrounding mental health issues encouraging more individuals to seek treatment during the forecast period (2024–2034).

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CORT_OUT_13 [2025-03-31 09:06:36 -0400] 238 Bytes | 59 tokens | Cum: 2212 tkns (27.65% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CORT_OUT_15 [2025-03-31 09:06:50 -0400] 8506 Bytes | 2506 tokens | Cum: 4721 tkns (59.01% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+------------------------+
| Volume: 653,632 | Perf Month: -8.72% | Option/Short: Yes / Yes | Sales Y/Y TTM: 39.94% |
+---------------------+-----------------------+-------------------------+------------------------+
| Avg Volume: 995.56K | Perf Quarter: 4.72% | Short Float: 17.53% | ROE: 23.55% |
+---------------------+-----------------------+-------------------------+------------------------+
| Rel Volume: 0.65 | Index: RUT | Short Ratio: 16.40 | ROI: 20.38% |
+---------------------+-----------------------+-------------------------+------------------------+
| RSI (14): 38.68 | Market Cap: 5.76B | Short Interest: 16.33M | Sales Surprise: -8.48% |
+---------------------+-----------------------+-------------------------+------------------------+
| ATR (14): 2.83 | Shs Outstand: 105.11M | Beta: 0.65 | EPS Surprise: -39.01% |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA20: -3.55% | Shs Float: 93.18M | Sales Q/Q: 34.33% | P/E: 44.30 |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA50: -11.20% | Inst Own: 80.21% | Sales past 5Y: 17.73% | Earnings: Feb 26 AMC |
+---------------------+-----------------------+-------------------------+------------------------+
| SMA200: 14.23% | Insider Own: 11.68% | Employees: 500 | |
+---------------------+-----------------------+-------------------------+------------------------+
| Perf Week: -6.87% | Insider Trans: -1.26% | Debt/Eq: 0.01 | |
+---------------------+-----------------------+-------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by Maduck Sean (See Remarks) on 2025-03-24
- Common Stock: 1697 shares at $5.05 (D)
- Common Stock: 1697 shares at $60.58 (D) Footnote: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
- Stock option (right to buy): 1697 shares at $0 (D)

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by BELANOFF JOSEPH K (Chief Executive Officer) on 2025-03-24
- Common Stock: 1974 shares at $60.8329 (I) Footnote: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by Lyon Joseph Douglas (See Remarks) on 2025-03-24
- Common Stock: 421 shares at $13.56 (D)
- Common Stock: 421 shares at $60.58 (D) Footnote: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
- Stock option (right to buy): 421 shares at $0 (D)

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by Robb Gary Charles (Chief Business Officer) on 2025-03-20
- Common Stock: 233 shares at $0 (I)
- Common Stock: 233 shares at $0 (I)

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by Robb Gary Charles (Chief Business Officer) on 2025-03-12
- Common Stock: 4625 shares at $0 (D)
- Common Stock: 1000 shares at $0 (I)
- Common Stock: 1000 shares at $0 (I)

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by Swisher Daniel N JR (Unknown Title) on 2025-03-10
- Common Stock: 2200 shares at $12.13 (D)
- Common Stock: 2200 shares at $53.6 (D) Footnote: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 1, 2024 in effect at the time of this transaction.
- Stock option (right to buy): 2200 shares at $0 (D)

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by BELANOFF JOSEPH K (Chief Executive Officer) on 2025-02-28
- Common Stock: 2924 shares at $60.909 (I) Footnote: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
- Stock option (right to buy): 350000 shares at $0 (D)

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by Guyer William (Chief Development Officer) on 2025-02-28
- Common Stock: 20000 shares at $19.26 (D)
- Common Stock: 20000 shares at $59.07 (D) Footnote: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
- Stock option (right to buy): 140000 shares at $0 (D)
- Stock option (right to buy): 20000 shares at $0 (D)

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by Lyon Joseph Douglas (See Remarks) on 2025-02-28
- Common Stock: 182 shares at $60.58 (D) Footnote: These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- Common Stock: 216 shares at $59.07 (D)
- Common Stock: 216 shares at $0 (D)
- Common Stock: 4579 shares at $13.56 (D)
- Common Stock: 4579 shares at $60.6905 (D) Footnote: The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
- Stock option (right to buy): 140000 shares at $0 (D)
- Stock option (right to buy): 4579 shares at $0 (D)

Inside Trans: CORCEPT THERAPEUTICS INC (CORT) by Maduck Sean (See Remarks) on 2025-02-28
- Common Stock: 228 shares at $60.58 (D) Footnote: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- Common Stock: 266 shares at $59.07 (D)
- Common Stock: 266 shares at $0 (D)
- Common Stock: 18303 shares at $5.05 (D)
- Common Stock: 18303 shares at $60.6905 (D) Footnote: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
- Stock option (right to buy): 140000 shares at $0 (D)
- Stock option (right to buy): 18303 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 675040000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 141209000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 54.63
Average Volume: 1089086.65
30-Day High: 59.47
30-Day Low: 54.3

[Detailed Financials: TTM 2024]
- Total Assets: $840,553,000.0
- Total Liabilities: $160,964,000.0
- Total Equity: $679,589,000.0
- Current Assets: $471,602,000.0
- Current Liabilities: $140,773,000.0

[Income Statement: TTM 2024]
- Revenue: $675,040,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 1.35

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-7,886,000.0

[Detailed Financials: FY 2024]
- Total Assets: $840,553,000.0
- Total Liabilities: $160,964,000.0
- Total Equity: $679,589,000.0
- Current Assets: $471,602,000.0
- Current Liabilities: $140,773,000.0

[Income Statement: FY 2024]
- Revenue: $675,040,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): 1.35

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-7,886,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CORT_OUT_17 [2025-03-31 09:06:52 -0400] 676 Bytes | 167 tokens | Cum: 5136 tkns (64.20% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CORT_IN_19 [2025-03-31 09:06:52 -0400] 126 Bytes | 29 tokens | Cum: 5193 tkns (64.91% of 8k)
==========================================================================

====================================
[2025-03-31 09:06:52] # Analysis Completed
Elapsed Time: 32.89 seconds